In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

(2010) Miguel Sanz et al.   CURRENT OPINION IN ONCOLOGY

Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

(2010) S. L. Holbeck et al.   MOLECULAR CANCER THERAPEUTICS

The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing

(2010) Caroline Haglund et al.   TOXICOLOGY LETTERS

Proteomic and Genetic Approaches Identify Syk as an AML Target

(2009) Cynthia K. Hahn et al.   CANCER CELL

A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours

(2009) Dominik Wolf et al.   DRUG SAFETY

Contemporary pre-clinical development of anticancer agents – What are the optimal preclinical models?

(2009) Giovanna Damia et al.   EUROPEAN JOURNAL OF CANCER

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison

(2008) Simone Boehrer et al.   BIOCHEMICAL PHARMACOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET

The fluorometric microculture cytotoxicity assay

(2008) Elin Lindhagen et al.   Nature Protocols